159 related articles for article (PubMed ID: 37950855)
1. Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L-glutamine, voxelotor, and crizanlizumab in sickle cell disease.
Chen M; Hankins JS; Zhang M; Ataga KI
Am J Hematol; 2024 Feb; 99(2):E37-E41. PubMed ID: 37950855
[TBL] [Abstract][Full Text] [Related]
2. Two drugs for sickle cell disease.
Med Lett Drugs Ther; 2020 Apr; 62(1595):51-52. PubMed ID: 32324178
[No Abstract] [Full Text] [Related]
3. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?
Leibovitch JN; Tambe AV; Cimpeanu E; Poplawska M; Jafri F; Dutta D; Lim SH
Blood Rev; 2022 May; 53():100925. PubMed ID: 34991920
[TBL] [Abstract][Full Text] [Related]
4. Sickle Cell Disease: A Review.
Kavanagh PL; Fasipe TA; Wun T
JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
[TBL] [Abstract][Full Text] [Related]
5. An update review of new therapies in sickle cell disease: the prospects for drug combinations.
Lugthart S; Ginete C; Kuona P; Brito M; Inusa BPD
Expert Opin Pharmacother; 2024 Feb; 25(2):157-170. PubMed ID: 38344818
[TBL] [Abstract][Full Text] [Related]
6. Expanded eligibility for emerging therapies in sickle cell disease in the UK - crizanlizumab and voxelotor.
Vora SM; Boyd S; Denny N; Jackson E; Roy NBA; Howard J; Lugthart S
Br J Haematol; 2022 May; 197(4):502-504. PubMed ID: 35189668
[No Abstract] [Full Text] [Related]
7. Voxelotor: A Novel Treatment for Sickle Cell Disease.
Herity LB; Vaughan DM; Rodriguez LR; Lowe DK
Ann Pharmacother; 2021 Feb; 55(2):240-245. PubMed ID: 32674605
[TBL] [Abstract][Full Text] [Related]
8. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
[TBL] [Abstract][Full Text] [Related]
9. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
10. Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease.
Çanak B; Eşkazan AE
Br J Clin Pharmacol; 2022 Jun; 88(6):2564-2565. PubMed ID: 35158414
[No Abstract] [Full Text] [Related]
11. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
[TBL] [Abstract][Full Text] [Related]
12. Clinical Practice Patterns in Sickle Cell Disease Treatment: Disease-modifying and Potentially Curative Therapies.
Sánchez LM; Morrone K; Frei-Jones M; Fasipe TA
J Pediatr Hematol Oncol; 2024 Jul; 46(5):e277-e283. PubMed ID: 38718300
[TBL] [Abstract][Full Text] [Related]
13. Real-world data on voxelotor to treat patients with sickle cell disease.
Muschick K; Fuqua T; Stoker-Postier C; Anderson AR
Eur J Haematol; 2022 Aug; 109(2):154-161. PubMed ID: 35460521
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
[TBL] [Abstract][Full Text] [Related]
15. Voxelotor for the treatment of sickle cell disease.
Vissa M; Vichinsky E
Expert Rev Hematol; 2021 Mar; 14(3):253-262. PubMed ID: 33602029
[No Abstract] [Full Text] [Related]
16. Voxelotor for the Treatment of Sickle Cell Disease.
Fantasia HC; Morse BL
Nurs Womens Health; 2020 Jun; 24(3):233-237. PubMed ID: 32387142
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
[TBL] [Abstract][Full Text] [Related]
18. Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease.
Lemon N; Sterk E; Rech MA
Am J Emerg Med; 2022 May; 55():225.e1-225.e3. PubMed ID: 34991907
[TBL] [Abstract][Full Text] [Related]
19. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine.
Migotsky M; Beestrum M; Badawy SM
Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]